MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

883.96 -33.69 (-3.67%)
Official Closing Price Updated: 7:00 PM EDT, Apr 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
My Top 3 Drug Stocks for March 2026 ↗
These companies have impressive track records of navigating the biggest challenges in their industry. 
Via The Motley Fool
Topics Intellectual Property
News headline image
2 Healthcare Stocks to Buy Before They Get Bought Out ↗
Abivax and Nektar Therapeutics are clinical-stage biotech companies that would make attractive buyout targets. 
Via The Motley Fool
News headline image
Best Growth Stock to Buy Right Now: Eli Lilly vs. Vertex Pharmaceuticals ↗
Both have plenty to offer investors, but one has a better outlook. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Eli Lilly Says Experimental Diabetes Drug Shows Weight Loss Of 17% ↗
Eli Lilly says retatrutide trial results show major weight loss and blood sugar improvements in the diabetes study. 
Via Benzinga
News headline image
Is It Too Late to Buy Eli Lilly? ↗
Eli Lilly's GLP-1 drugs are leaders in a new and exciting drug category, but investors already know this fact. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Should You Buy the Vanguard S&P 500 ETF After the Recent Stock Market Sell-Off? History Offers a Crystal-Clear Answer. ↗
Volatility in the stock market often leads to great long-term opportunities for investors. 
Via The Motley Fool
Topics ETFs Economy Stocks
News headline image
1 Reason I'm Never Selling Novo Nordisk Stock ↗
I am not turned off by the company's recent setbacks. 
Via The Motley Fool
News headline image
Eli Lilly's Experimental Drug Retatrutide Delivers Strong Weight Loss In Late-Stage Trial ↗
Patients taking retatrutide, lost 16.8% of their body weight over 40 weeks. 
Via Investor's Business Daily
News headline image
AbbVie Shares Retreat to Multi-Month Lows Amid Competitive Headwinds and Technical Breakdown
The pharmaceutical giant AbbVie (NYSE: ABBV) experienced a sharp decline on Wednesday, March 18, 2026, as its stock price tumbled to its lowest level since mid-2025. Shares of the Illinois-based... 
Via MarketMinute
Topics ETFs Economy Intellectual Property
News headline image
Stock Of The Day: Is The Eli Lilly Selloff Over? ↗
Eli Lilly shares made a large move lower. But they are oversold and getting close to a level where there may be support. 
Via Benzinga
News headline image
Ardsley Dumps 440,000 Hut 8 Shares Worth $19.4 Million ↗
Hut 8 operates large-scale data centers supporting Bitcoin mining and high-performance computing for institutional clients. 
Via The Motley Fool
Topics Artificial Intelligence Regulatory Compliance
News headline image
The High-Stakes Gambit: How Healthcare Giants are 'Front-Loading' Megadeals to Outrun Regulatory Storms
In the face of the most aggressive antitrust environment in decades and the sweeping legislative changes of the 2025 "One Big Beautiful Bill Act" (OBBBA), the healthcare sector has not retreated from... 
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
News headline image
Hims & Hers (HIMS) 2026 Deep Dive: The $1.15B Eucalyptus Deal and the Branded Pivot
As of March 18, 2026, Hims & Hers Health (NYSE: HIMS) has reclaimed its position as the primary protagonist in the direct-to-consumer (DTC) healthcare narrative. Following a turbulent start to the year... 
Via Finterra
Topics Intellectual Property
News headline image
Members of Congress Bought These 5 Stocks—Should You? ↗
Via MarketBeat
Airlines Take Flight While Oil Burns: Markets Edge Higher Amid Middle East Tensions ↗
Via Chartmill
News headline image
Branded Pharmaceuticals Stocks Q4 Recap: Benchmarking Zoetis (NYSE:ZTS)
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Zoetis (NYSE:ZTS) and its peers. Looking ... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Better Weight Loss Drug Stock Buy: Eli Lilly vs Viking Therapeutics ↗
Each of these companies could benefit from this high-growth market over time. 
Via The Motley Fool
News headline image
Top 2 S&P 500 Stocks to Watch This Week After Hims & Hers Stock's Surprise Move ↗
These companies are benefiting from a tidal wave of demand for new weight-loss drugs. 
Via The Motley Fool
Topics Stocks
News headline image
Stock Market Today, March 17: Markets Edge Upwards as Fed Meeting Opens ↗
Today, March 17, 2026, selective tech gains helped lift the Nasdaq even as oil prices and geopolitical tensions stayed elevated. 
Via The Motley Fool
Topics Economy Stocks
News headline image
Why Eli Lilly (LLY) Shares Are Plunging Today
What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 6.3% in the afternoon session after investment bank HSBC downgraded the stoc... 
Via StockStory
News headline image
Worried the AI Hype Won't Last? These Dividend Stocks Offer Safer Exposure ↗
You don't have to go all in to profit from AI. 
Via The Motley Fool
Topics Artificial Intelligence
Which S&P500 stocks are moving on Tuesday? ↗
Via Chartmill
News headline image
LLY Shares Dive On Analyst Downgrade Citing Obesity Market Overestimation Concerns, But Retail Dismisses ‘Absurd’ Selloff ↗
The analyst’s new price target represents a potential downside of about 14% from the stock’s last closing price on Monday. 
Via Stocktwits
Tuesday's session: top gainers and losers in the S&P500 index ↗
Via Chartmill
News headline image
Why Eli Lilly Stock Just Dropped ↗
Eli Lilly's stock price is based on growth rates that might fall short. 
Via The Motley Fool
News headline image
Eli Lilly Analyst Flags Overhyped Obesity Drug Expectations ↗
HSBC downgrades Eli Lilly to reduce, citing pricing pressure, rising competition, and overestimated obesity drug market growth expectations. 
Via Benzinga
Tuesday's session: gap up and gap down stock in the S&P500 index ↗
Via Chartmill
News headline image
This Promising GLP-1 Drug Could Give Novo Nordisk Investors Renewed Hope for the Stock ↗
Novo Nordisk recently announced promising trial results for one of its GLP-1 drugs in development. 
Via The Motley Fool
News headline image
Should You Avoid Pfizer? Here's the Key Risk to Watch ↗
Pfizer has reached a turning point. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Is There Too Much Bullishness Priced Into Eli Lilly's Stock Price? ↗
Eli Lilly's stock is down this year, and its high valuation may be a big reason why. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story